Premune Joins Leaders in Healthcare Innovation at 2015 OneMedForum

NEW YORK, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Premune, a development stage biopharmaceutical company focused on translating medical advances to make meaningful differences in the health and well being of companion animals, will present at the 8th Annual OneMedForum at the San Francisco Marriot Marquis in San Francisco, CA, United States on Monday, January 12, 2015. The OneMedForum conference brings together life science company executives and investors involved in building the future of health and medicine as well as investor and healthcare media.

Viktor Karlsson, Chief Executive Officer and co-founder of Premune Inc., will provide an overview of the company's business and development efforts during a live presentation and will be available to participate in one-on-one meetings with investors and potential business partners who will be attending the Forum.

Event: 8th Annual OneMedForum
Date: Monday, January 12, 2015
Time: 3:15 p.m.
Location: Marriot Marquis, San Francisco, CA, USA

The presentation will be recorded and will be available on the Premune website and on OneMedTV for 30 days following the presentation. To access the presentation, please visit the investor relations section of the Premune website at

About Premune

Premune is a development stage biopharmaceutical company focused on developing novel treatments for allergies and autoimmune-related disorders in companion animals. The Company's product candidates seek to target conditions that are common in pets such as allergies and inflammatory diseases. Premune's current product candidates are built on years of collective research in bacteriology and immunology by its scientific team at leading Swedish research institutions, including the University of Gothenburg and Sahlgrenska University Hospital. The Company is continuously seeking to expand its product candidate portfolio through a combination of in-house research and development projects and in-licensing additional product candidates. Premune aims to advance its product candidates through clinical development and introduce them into the companion animal health market.

Forward-Looking and Cautionary Statements: Statements contained in this release may constitute "forward-looking statements." These statements may be identified by words such as "expects," "looks forward to," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," "project" or words of similar meaning. Such statements are based on the current expectations and certain assumptions of Premune's management and are subject to certain risks and uncertainties. A variety of factors, many of which are beyond Premune's control, can affect the operations, performance, development of products, business strategy, timing and results. Without limiting the foregoing, the development, testing, regulatory approval process and the timeline associated with development, manufacture and sale of therapeutic products in the animal health industry are inherently uncertain. Premune is neither required nor intends to publicly update or revise any forward-looking statements.

CONTACT: For investor inquiries: Michio Soga Premune, Inc. +1 646 780 7645 For media inquiries: Mickey McDermott Premune, Inc. +1 646 780 7647

Source: Premune